الفهرس 
CHRONIC KIDNEY DISEASEOnly 14 pages are availabe for public view
 |  | from | 181 |  |  |
| | | from | 181 | | |
Abstract
• Serum fetuin-A as a biomarker for early identification of ESRD patients who are at high risk of cardiovascular disease, shows a sustained decrease of which might account for accelerated atherogenesis and increased risk of mortality.
• The effectiveness of serum fetuin-A as a predictive biomarker for cardiovascular disease in hemodialysis patients is increased when it is employed in combination with other proven biomarkers, such as hs-CRP and homocysteine.
• Further studies are needed to assess the functional activity of fetuin-A and to investigate if other factors, such as changes in residual renal function, acid-base balance, or nutritional changes may cause a decline of fetuin-A levels during hemodialysis.
• Future research studies are needed to evaluate the potential clinical utility of fetuin-A as a novel therapeutic agent to prevent ectopic calcification accompanying various diseases.